Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 26 | 2023 | 1243 | 6.200 |
Why?
|
| Proton Therapy | 13 | 2023 | 123 | 4.880 |
Why?
|
| Survivors | 15 | 2022 | 339 | 3.880 |
Why?
|
| Cancer Survivors | 8 | 2023 | 204 | 3.050 |
Why?
|
| Cerebellar Neoplasms | 6 | 2024 | 285 | 2.750 |
Why?
|
| Medulloblastoma | 5 | 2024 | 340 | 2.540 |
Why?
|
| Craniospinal Irradiation | 6 | 2023 | 58 | 2.420 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2021 | 779 | 2.150 |
Why?
|
| Cognition | 8 | 2023 | 730 | 1.900 |
Why?
|
| Adaptation, Psychological | 3 | 2024 | 451 | 1.760 |
Why?
|
| Mutism | 2 | 2024 | 29 | 1.660 |
Why?
|
| Intelligence | 6 | 2023 | 98 | 1.490 |
Why?
|
| Photons | 3 | 2021 | 48 | 1.330 |
Why?
|
| Cognition Disorders | 5 | 2019 | 553 | 1.300 |
Why?
|
| Child | 43 | 2024 | 24435 | 1.080 |
Why?
|
| Executive Function | 3 | 2021 | 105 | 1.010 |
Why?
|
| Protons | 6 | 2023 | 91 | 1.010 |
Why?
|
| Survivorship | 2 | 2023 | 36 | 0.990 |
Why?
|
| Neurocognitive Disorders | 3 | 2021 | 67 | 0.970 |
Why?
|
| Attention | 4 | 2017 | 196 | 0.970 |
Why?
|
| Craniopharyngioma | 2 | 2023 | 33 | 0.940 |
Why?
|
| Pituitary Neoplasms | 2 | 2023 | 84 | 0.890 |
Why?
|
| Intelligence Tests | 3 | 2022 | 57 | 0.880 |
Why?
|
| Adolescent | 29 | 2024 | 19300 | 0.860 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2016 | 226 | 0.830 |
Why?
|
| Cerebellar Diseases | 1 | 2022 | 75 | 0.750 |
Why?
|
| Cognitive Dysfunction | 2 | 2023 | 232 | 0.740 |
Why?
|
| Neuropsychological Tests | 10 | 2024 | 925 | 0.720 |
Why?
|
| Language Development Disorders | 1 | 2022 | 174 | 0.710 |
Why?
|
| Memory, Short-Term | 2 | 2019 | 140 | 0.710 |
Why?
|
| Male | 36 | 2024 | 60967 | 0.620 |
Why?
|
| Cisplatin | 1 | 2019 | 238 | 0.610 |
Why?
|
| Social Class | 1 | 2019 | 191 | 0.590 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 141 | 0.590 |
Why?
|
| Female | 36 | 2024 | 66235 | 0.590 |
Why?
|
| Medical Oncology | 4 | 2024 | 207 | 0.580 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 404 | 0.560 |
Why?
|
| Child, Preschool | 13 | 2024 | 14042 | 0.560 |
Why?
|
| Humans | 50 | 2024 | 124307 | 0.540 |
Why?
|
| Aptitude | 1 | 2016 | 12 | 0.530 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 307 | 0.530 |
Why?
|
| Smoking | 3 | 2011 | 1037 | 0.530 |
Why?
|
| Social Adjustment | 3 | 2022 | 84 | 0.510 |
Why?
|
| Child Development | 1 | 2016 | 265 | 0.440 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 811 | 0.420 |
Why?
|
| Neoplasms | 5 | 2023 | 2761 | 0.370 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1322 | 0.370 |
Why?
|
| Smoking Prevention | 1 | 2011 | 37 | 0.370 |
Why?
|
| Mentors | 3 | 2023 | 143 | 0.370 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2023 | 197 | 0.350 |
Why?
|
| Surveys and Questionnaires | 5 | 2024 | 3722 | 0.350 |
Why?
|
| Intention | 1 | 2010 | 92 | 0.340 |
Why?
|
| Aggression | 1 | 2010 | 225 | 0.300 |
Why?
|
| Feeding Behavior | 1 | 2014 | 712 | 0.290 |
Why?
|
| Quality of Life | 3 | 2023 | 1943 | 0.290 |
Why?
|
| Body Mass Index | 1 | 2014 | 1547 | 0.290 |
Why?
|
| Brain | 3 | 2023 | 3002 | 0.280 |
Why?
|
| Prognosis | 4 | 2020 | 4549 | 0.280 |
Why?
|
| Mentoring | 2 | 2019 | 75 | 0.280 |
Why?
|
| Radiation Injuries | 2 | 2019 | 142 | 0.280 |
Why?
|
| Glioma | 2 | 2021 | 500 | 0.270 |
Why?
|
| Young Adult | 8 | 2023 | 8974 | 0.260 |
Why?
|
| Emotions | 2 | 2024 | 364 | 0.260 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5105 | 0.260 |
Why?
|
| Wechsler Scales | 2 | 2016 | 20 | 0.240 |
Why?
|
| Adult | 11 | 2024 | 29385 | 0.220 |
Why?
|
| Nurse-Patient Relations | 1 | 2002 | 16 | 0.210 |
Why?
|
| Nursing | 1 | 2002 | 11 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 142 | 0.200 |
Why?
|
| Patient Preference | 1 | 2023 | 119 | 0.200 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 52 | 0.190 |
Why?
|
| Infant | 5 | 2023 | 12473 | 0.190 |
Why?
|
| Perception | 1 | 2002 | 220 | 0.180 |
Why?
|
| Parents | 4 | 2023 | 1029 | 0.180 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3069 | 0.180 |
Why?
|
| Neuropsychology | 1 | 2020 | 23 | 0.170 |
Why?
|
| Research | 1 | 2022 | 263 | 0.170 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 169 | 0.160 |
Why?
|
| Syndrome | 1 | 2022 | 1118 | 0.160 |
Why?
|
| Program Evaluation | 2 | 2019 | 447 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2020 | 4731 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 170 | 0.150 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 235 | 0.150 |
Why?
|
| Transition to Adult Care | 1 | 2020 | 120 | 0.150 |
Why?
|
| Caregivers | 1 | 2023 | 577 | 0.150 |
Why?
|
| Oncologists | 1 | 2017 | 29 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1658 | 0.140 |
Why?
|
| Pediatricians | 1 | 2017 | 66 | 0.140 |
Why?
|
| School Teachers | 1 | 2016 | 8 | 0.130 |
Why?
|
| Fatigue | 3 | 2022 | 193 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1244 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2023 | 12292 | 0.130 |
Why?
|
| Sample Size | 1 | 2016 | 85 | 0.130 |
Why?
|
| Reaction Time | 1 | 2016 | 170 | 0.130 |
Why?
|
| Observer Variation | 1 | 2016 | 299 | 0.120 |
Why?
|
| Bereavement | 1 | 2005 | 19 | 0.120 |
Why?
|
| Professional-Family Relations | 1 | 2005 | 91 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2023 | 16228 | 0.110 |
Why?
|
| Linear Models | 1 | 2016 | 670 | 0.110 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 69 | 0.110 |
Why?
|
| Terminal Care | 1 | 2005 | 112 | 0.110 |
Why?
|
| Self Report | 1 | 2016 | 520 | 0.110 |
Why?
|
| Clinical Nursing Research | 1 | 2002 | 5 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 872 | 0.100 |
Why?
|
| Nursing Assessment | 1 | 2002 | 24 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2013 | 136 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2020 | 6071 | 0.100 |
Why?
|
| Behavioral Symptoms | 1 | 2012 | 25 | 0.100 |
Why?
|
| Risk Factors | 3 | 2017 | 10141 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2005 | 388 | 0.090 |
Why?
|
| Family | 1 | 2005 | 565 | 0.090 |
Why?
|
| Age Factors | 2 | 2021 | 2802 | 0.090 |
Why?
|
| Cranial Irradiation | 1 | 2012 | 69 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3425 | 0.090 |
Why?
|
| Divorce | 1 | 2010 | 6 | 0.090 |
Why?
|
| Social Behavior | 1 | 2012 | 209 | 0.090 |
Why?
|
| Palliative Care | 1 | 2005 | 431 | 0.090 |
Why?
|
| Methylphenidate | 1 | 2010 | 57 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2012 | 175 | 0.090 |
Why?
|
| Canada | 1 | 2011 | 299 | 0.090 |
Why?
|
| Health Surveys | 1 | 2011 | 244 | 0.090 |
Why?
|
| Central Nervous System Stimulants | 1 | 2010 | 126 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1268 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2012 | 539 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1415 | 0.070 |
Why?
|
| United States | 2 | 2011 | 10766 | 0.060 |
Why?
|
| Logistic Models | 1 | 2010 | 1802 | 0.060 |
Why?
|
| Communication | 2 | 2005 | 516 | 0.060 |
Why?
|
| Research Personnel | 1 | 2024 | 118 | 0.050 |
Why?
|
| Career Choice | 1 | 2024 | 143 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2023 | 186 | 0.050 |
Why?
|
| Time Factors | 1 | 2013 | 6272 | 0.050 |
Why?
|
| Verbal Learning | 1 | 2022 | 66 | 0.050 |
Why?
|
| Pediatrics | 2 | 2024 | 1154 | 0.050 |
Why?
|
| Middle Aged | 3 | 2023 | 26452 | 0.050 |
Why?
|
| Focus Groups | 1 | 2002 | 201 | 0.050 |
Why?
|
| Telomerase | 1 | 2021 | 160 | 0.040 |
Why?
|
| Professional Role | 1 | 2020 | 57 | 0.040 |
Why?
|
| Health Personnel | 1 | 2024 | 505 | 0.040 |
Why?
|
| Models, Psychological | 1 | 2020 | 138 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 340 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2021 | 810 | 0.040 |
Why?
|
| DNA Repair | 1 | 2021 | 589 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1401 | 0.040 |
Why?
|
| Career Mobility | 1 | 2017 | 50 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2017 | 102 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 419 | 0.030 |
Why?
|
| Pandemics | 1 | 2024 | 1103 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 1422 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1660 | 0.030 |
Why?
|
| Texas | 1 | 2023 | 3581 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1254 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 3137 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 859 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 6469 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 2971 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2002 | 231 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2002 | 358 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2005 | 557 | 0.020 |
Why?
|
| Faculty | 1 | 2010 | 101 | 0.020 |
Why?
|
| Educational Status | 1 | 2010 | 271 | 0.020 |
Why?
|
| Decision Making | 1 | 2005 | 654 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 2039 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 2867 | 0.020 |
Why?
|
| Aged | 1 | 2002 | 19481 | 0.010 |
Why?
|